Your browser doesn't support javascript.
loading
Current pharmacotherapy of overactive bladder.
Kreydin, Evgenyi I; Gomes, Cristiano M; Cruz, Francisco.
  • Kreydin EI; Department of Urology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
  • Gomes CM; Divisão de Urologia, Departamento de Cirurgia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.
  • Cruz F; Departamento de Urologia, Hospital de S. João, Faculdade de Medicina do Porto, Porto, Portugal.
Int Braz J Urol ; 47(6): 1091-1107, 2021.
Article en En | MEDLINE | ID: mdl-34003613
ABSTRACT
Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva Límite: Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva Límite: Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article